								Page 1 of 1	
FORM PTO	1449			INT'L FILIN	VC NO	10/596	503		
		DISCLOSURE ST	ATEMENT	INT'L FILING DATE			6/15/06		
I'm OKILLI		DISCLOSURESI	ALLMAN		APPLICANT		Bailey et al.		
					GROUP		1624	GC GL.	
					EXAMINER ATTORNEY DOCKET NO.			Coleman	
			U.S. I	T	OCUMENTS			Filing Date	
Examiner Initials		Patent Number	Issue Date	Name		Class	Subclass	If Appropriate	
/B.C./	1.	4,210,749	7/1/1980	Shetty		540	594		
/B.C./	2.	5,364,791	11/15/1994	Vegeto et al.		435	320.1		
/B.C./	3.	5,874,534	2/23/1999	Vegeto eta L		530	350		
/B.C./	4.	5,935,934	10/10/1999	Vegeto et		514	44		
70.01	4.	3,933,934	10/10/1999	vegeto et	aı.	72.4	1 2 2	-	
	_		-				-		
			-	-			-		
		·	FORFIC	N PATEN	T DOCUMENT	re	٠		
	FOREIGN PATENT DOCUMENTS Document Publication						Translation		
		Number	Publication Date		Country	Class	Subclass	Yes No	
/B.C./	ο.	WO 96/05194	2/2/1996	PCT				abstract only	
** /B.C./	6.	WO 00/23437	4/27/2000	PCT				abstract only	
** /B.C./	7.	WO 02/02530	1/10/2002	PCT				abstract only	
/B.C./	8.	WO 01/03680	1/18/2001	PCT					
** /B.C./	9.	WO 01/87834	11/22/2001	PCT					
** /B.C./	10.	WO 02/14513	2/21/2002	PCT			1	abstract only	
/B.C./	11.	WO 00/21951	4/20/2000	PCT					
** /B.C./	12.	WO 02/15934	2/28/2002	PCT				abstract only	
** /B.C./	13.	WO 02/46186	6/13/2002	PCT				abstract only	
/B.C./	14.	WO 03/68751	8/21/2003	PCT			i		
/B.C./	15.	WO 03/68752	8/21/2003	PCT					
/B.C./	16.	WO 03/95428	11/20/2003	PCT					
/B.C./	17.	WO 04/56369	7/8/2004	PCT			1		
/B.C./	18.	1 331 010	7/30/2003	EP					
** /B.C./	19.	2207430	7/23/1981	DE			†	abstract only	
** /B.C./	20.	2171879	9/28/1973	FR		_		abstract only	
/B.C./	21.	1 268 243	3/22/1972	GB			1	ubstract only	
** /B.C./	22.	2001226269	8/21/2001	JP			1	abstract only	
	22.				Title Iournal	Data Paga Vin	nhar Etc.)	abstract only	
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) 23. GIOVANNINI et al., "Effects of histamine H ₃ receptor agonists and antagonists on cognitive								a narformanca	
/B.C./	23.	GIOVANNINI et al., "Effects of histamine H ₃ receptor agonista and antagonists on cognitive performance and scopolamine-induced amnesia," Behavirural Brain Res. 104:147-155 (1999). LEURS et al., "Therapeutic potential of histamine H ₃ receptor agonists and antagonists," TiPS 19:177-183 (May 1998).							
	24.								
/B.C./	24.								
/B.C./	25.								
/6.0./	125.								
	26.	ONODER A and	WATANADE "	Histomina L	I Antagoniste a	e Potential Ther	opoutice in the	CMS 2 ad Laure	
/B.C./	1 20.	ONODERA and WATANABE, "Histamine H ₃ Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).							
	27.					via hietamina U	heterorecento	re " Fundam Clin	
/B.C./	² /·	SCHLICKER et al., "Modulation of neurotransmitter release via histamine H ₃ heteroreceptors," Fundam Clin							
	28.	Pharmacol 8:128-137 (1994). STARK, Recent advances in histamine H ₂ /H ₄ receptor ligands, Expert Opinion on Therapeutic Patents							
/B.C./	1 ^{20.}	13(6):851-865 (2							
	\vdash	15(0).051-005 (2							
	-								
	\vdash								
EXAMINER						I DATE	CONCIDENT	D	
CAAMUNER		/Brenda Coleman/				DATE	DATE CONSIDERED 09/05/2008		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.